Liso-Cel Receives Accelerated Approval for Relapsed or Refractory Follicular Lymphoma | Blood Cancers Today
The US FDA has granted accelerated approval for liso-cel in adult patients with relapsed or refractory follicular lymphoma.
The US FDA has granted accelerated approval for liso-cel in adult patients with relapsed or refractory follicular lymphoma.
Findings indicate that supervised HiRIT provides a positive stimulus to cortical bone at the medial FN compared with supervised IAC exercise, and both HiRIT and…
A recent study has highlighted the potential benefits of a plant-based diet in reducing the risk of gout, which affects 4% of Americans.
Momelotinib led to āsuperiorā symptom and spleen responses and transfusion independence rates compared to danazol in thrombocytopenic myelofibrosis.
Find critical updates in hematologic oncology from the European Hematology Association 2024 Congress, held from June 13-16, 2024, in Madrid, Spain.
AbstractBackgroundLeft atrial appendage occlusion (LAAO) provides mechanical cardioembolic protection for atrial fibrillation (AF) patients who cannot use oral anticoagulation therapy (OAT). Patien…
Dr. Margaret Gatti-Mays explains what makes The Oncology Brothers’ content so important for community oncologists.
AbstractRecent artificial intelligence (AI) advancements in cardiovascular care offer potential enhancements in effective diagnosis, treatment, and outcomes. More than 600 U.S. Food and Drug Admini…
Find critical updates in hematologic oncology from the European Hematology Association 2024 Congress, held from June 13-16, 2024, in Madrid, Spain.
This issue of Blood Cancers Today includes a feature on secondary malignancies after CAR T-cell therapy; a Get to Know with Julie Vose, MD; and…
Make a difference today in a blood cancer patient’s life by supporting The Leukemia & Lymphoma Society https://givenow.lls.org/give/342076/#!/donation/checkout